Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;17(2):e29-e33.
doi: 10.14797/ICHN7633. eCollection 2021.

Chronic Thromboembolic Pulmonary Hypertension Medical Management

Ryan Logue  1 , Zeenat Safdar  1
Affiliations

Chronic Thromboembolic Pulmonary Hypertension Medical Management

Ryan Logue et al. Methodist Debakey Cardiovasc J. .

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a common long-term complication of pulmonary embolism characterized by thromboembolic obstruction of the pulmonary arteries, vascular arteriopathy, vascular remodeling, and ultimately pulmonary hypertension (PH). Although pulmonary endarterectomy (PEA) surgery is the standard of care, approximately 40% of patients in the international CTEPH registry were deemed inoperable. In addition to lifelong anticoagulation, the cornerstone of PH-specific medical management is riociguat, a soluble guanylate cyclase stimulator. Medical management should be started early in CTEPH patients and may be used as a bridge to PEA surgery or balloon pulmonary angiography. Medical management is indicated for inoperable CTEPH patients and patients who have recurrence of PH after PEA surgery.

Keywords: CTEPH; chronic thromboembolic pulmonary hypertension; pulmonary embolism; pulmonary endarterectomy; riociguat.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001. November 15; 345(20): 1465–72. doi: 10.1056/NEJMra010902. - DOI - PubMed
    1. Medrek S, Safdar Z. Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms. Methodist Debakey Cardiovasc J. 2016. Oct-Dec; 12(4): 195–198. doi: 10.14797/mdcj-12-4-195. - DOI - PMC - PubMed
    1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013. December 24; 62(25 Suppl): D34–41. doi: 10.1016/j.jacc.2013.10.029. - DOI - PubMed
    1. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013. February; 41(2): 462–8. doi: 10.1183/09031936.00049312. - DOI - PubMed
    1. Schweikert B, Pittrow D, Vizza CD, et al. Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. BMC Health Serv Res. 2014. June 9; 14: 246. doi: 10.1186/1472-6963-14-246. - DOI - PMC - PubMed

MeSH terms